Bulletin of Experimental Biology and Medicine

, Volume 86, Issue 3, pp 1171–1173 | Cite as

Effect of imipramine-like antidepressants on head twitching in mice induced by 5-hydroxytryptophan

  • E. L. Shelkunov


When headtwitching (HT) in mice in response to administration of 5-hydroxytryptophan (5-HTP) was used as a “serotoninergic” model the antidepressants chlorimipramine and imipramine, and also chlorpheniramine (suprastin), exhibited a serotonin-positive action in doses of 1.0, 5.0, and 1.0 mg/kg respectively. Quipazine had a serotoninomimetic action, desipramine an ambivalent action in doses of 1–20 mg/kg, whereas iprindole and morphaphen were ineffective in doses of up to 20 mg/kg. Amitryptiline, noveril (dibenzepine), melitracene, trimeprimine (trimipramine), and ludiomil (maprotiline) exhibited an antiserotonin action in doses of 0.5, 1.0, 20.0, and 20.0 mg/kg respectively. The results are discussed in the light of the concept of a complex spectrum of mediator activity of the imipramine-like antidepressant.

Key Words

antidepressants anti- and proserotonin action screening 5-hydroxytryptophan head twitching 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literature Cited

  1. 1.
    A. P. Gilev, V. Zh. Kurilenko, T. M. Vysokovskii, et al., in: The Pharmacological Basis of the Antidepressive Effect [in Russian], Leningrad (1970), p. 75.Google Scholar
  2. 2.
    I. P. Lapin, G. F. Oksenbrug, I. V. Ryzhov, et al., Farmakol. Toksikol., No. 2, 144 (1976).Google Scholar
  3. 3.
    G. F. Oksenkrug, S. V. Osipova, and N. V. Uskova, in: Serotoninergic Processes in the Action of Psychotropic Drugs [in Russian], Leningrad (1970), p. 47.Google Scholar
  4. 4.
    E. Zh. Shelkunov, in: Serotoninergic Processes in the Action of Psychotropic Drugs [in Russian], Leningrad (1970), p. 150.Google Scholar
  5. 5.
    E. L. Shelkunov, in: Depressions and Their Treatment [in Russian], Leningrad (1973), p. 131.Google Scholar
  6. 6.
    B. B. Brodie and P. A. Shore, Ann. New York Acad. Sci.,66, 631 (1957).Google Scholar
  7. 7.
    A. Carlsson, H. Corrodi, K. Fuxe, et al., Europ. J. Pharmacol.,5, 357 (1969).Google Scholar
  8. 8.
    S. J. Corne and R. W. Pickering, Psychopharmacologia (Berlin),11, 65 (1967).Google Scholar
  9. 9.
    I. P. Lapin and G. F. Oxenkrug (G. F. Oksenkrug), Lancet,1, 132 (1969).Google Scholar
  10. 10.
    P. Lidbrink, G. Jonsson, and K. Fuxe, Neuropharmacology,10, 521 (1971).Google Scholar
  11. 11.
    A. Randrup and C. Braestrup, Psychopharmacology,53, 309 (1977).Google Scholar
  12. 12.
    R. Rodrigues, J. A. Rojas-Ramirez, and R. R. Drucker-Colin, Europ. J. Pharmacol.,24, 164 (1973).Google Scholar
  13. 13.
    S. B. Ross and A. L. Renyi, Europ. J. Pharmacol.,7, 270 (1969).Google Scholar
  14. 14.
    E. L. Schelkunov (E. L. Shelkunov), Activ. Nerv. Sup. (Prague),9, 207 (1967).Google Scholar
  15. 15.
    W. Theobald, A. Büsch, and H. A. Kunz, Arzneimittel-Forsch.,15, 117 (1965).Google Scholar

Copyright information

© Plenum Publishing Corporation 1979

Authors and Affiliations

  • E. L. Shelkunov

There are no affiliations available

Personalised recommendations